Savia de Souza

Savia de Souza

Auto-generated profile, based on publicly available information

Savia de Souza

Centre For Rheumatic Diseases, King’s College London, London, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JSJosef S Smolen
Josef S Smolen
RLRobert B M Landewé
Robert B M Landewé
SBSytske Anne Bergstra
Sytske Anne Bergstra
AKAndreas Kerschbaumer
Andreas Kerschbaumer
Alexandre SeprianoAlexandre Sepriano
Alexandre Sepriano
DHDésirée van der Heijde
Désirée van der Heijde
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item. Results The task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3–6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations. Conclusions These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost.

8 March 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JGJames M Gwinnutt
James M Gwinnutt
MWMaud Wieczorek
Maud Wieczorek
ABAndra Balanescu
Andra Balanescu
HBHeike A Bischoff-Ferrari
Heike A Bischoff-Ferrari
ABAnnelies Boonen
Annelies Boonen
SVSuzanne M M Verstappen
Suzanne M M Verstappen
Objectives A European League Against Rheumatism taskforce was convened to review the literature and develop recommendations on lifestyle behaviours for rheumatic and musculoskeletal diseases (RMDs). Methods Six lifestyle exposures (exercise, diet, weight, alcohol, smoking, work participation) and seven RMDs (osteoarthritis, rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, systemic sclerosis, gout) were considered. The taskforce included health professionals in rheumatology, geriatricians, epidemiologists, public health experts, people with RMDs and exposure domain experts. Systematic reviews were conducted to gather available evidence, from which recommendations were developed. Results Five overarching principles and 18 specific recommendations were defined based on available evidence. The overarching principles define the importance of a healthy lifestyle, how lifestyle modifications should be implemented, and their role in relation to medical treatments. Exercise recommendations highlight the safety and benefits of exercise on pain and disability, particularly among people with osteoarthritis and axial spondyloarthritis. The diet recommendations emphasise the importance of a healthy, balanced diet for people with RMDs. People with RMDs and health professionals should work together to achieve and maintain a healthy weight. Small amounts of alcohol are unlikely to negatively affect the outcomes of people with RMDs, although people with rheumatoid arthritis and gout may be at risk of flares after moderate alcohol consumption. Smokers should be supported to quit. Work participation may have benefits on RMD outcomes and should be discussed in consultations. Conclusions These recommendations cover a range of lifestyle behaviours and can guide shared decision making between people with RMDs and health professionals when developing and monitoring treatment plans.

11 November 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
AKAndreas Kerschbaumer
Andreas Kerschbaumer
Alexandre SeprianoAlexandre Sepriano
Alexandre Sepriano
SBSytske Anne Bergstra
Sytske Anne Bergstra
JSJosef S Smolen
Josef S Smolen
DHDésirée van der Heijde
Désirée van der Heijde
RLRobert B M Landewé
Robert B M Landewé

14 November 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
Alexandre SeprianoAlexandre Sepriano
Alexandre Sepriano
AKAndreas Kerschbaumer
Andreas Kerschbaumer
SBSytske Anne Bergstra
Sytske Anne Bergstra
JSJosef S Smolen
Josef S Smolen
DHDésirée van der Heijde
Désirée van der Heijde
RLRobert B M Landewé
Robert B M Landewé

21 November 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SBSytske Anne Bergstra
Sytske Anne Bergstra
Alexandre SeprianoAlexandre Sepriano
Alexandre Sepriano
AKAndreas Kerschbaumer
Andreas Kerschbaumer
DHDésirée van der Heijde
Désirée van der Heijde
RCRoberto Caporali
Roberto Caporali
RLRobert B M Landewé
Robert B M Landewé

6 January 2016 in Journal of Foot and Ankle Research
Verified
Journal Article
Open access
PDF file
SSSavia de Souza
Savia de Souza
RWRuth Williams
Ruth Williams
HLHeidi Lempp
Heidi Lempp
Background: Feet are often the first site of joint involvement in rheumatoid arthritis (RA) and get progressively worse if unmanaged, leading to permanent disability and negatively impacting patients' quality of life. Podiatrists are specialists in the assessment, diagnosis and management of foot and ankle problems, however, RA outpatients often rely on referral from rheumatology clinicians to gain access to musculoskeletal podiatry services on the UK National Health Service (NHS). Therefore, the aim of this evaluation was to identify the foot health needs of rheumatoid arthritis patients and if they are being met by rheumatology clinicians.Methods: A mixed methods approach was used: collecting qualitative data from patients and quantitative data from clinicians. Two focus groups were conducted with nine RA patients from a tertiary rheumatology outpatient clinic in the UK and the data were thematically analysed to inform a clinician survey. Thirteen rheumatology clinicians, from the same centre, completed the online survey. Resultant data were analysed to produce descriptive statistics.Results: Patient focus group data generated four main themes: (1) need for foot health information, (2) feet ignored during routine consultations, (3) frequency of foot examination and (4) access to podiatry. Survey data highlighted that (i) 69–85 % of clinicians provided patients with foot health information sometimes, (ii) feet were examined in 47 % of routine consultations, (iii) 54 % of clinicians did not examine feet routinely because they are not included in the disease activity score with 28 joints (DAS‐28), (iv) 31 % of clinicians referred patients to podiatry upon RA diagnosis, (v) 0 % of clinicians referred patients to podiatry for periodic review, (vi) 54 % of clinicians believed patients will self‐report foot problems and (vii) 62 % of clinicians felt competent in foot examination.Conclusions: RA patients' foot health needs were not being fully met by rheumatology clinicians. Patients want foot health information and easy access to podiatry services. Rheumatology outpatient consultations need to have a wider focus than the DAS‐28 and incorporate foot examination as standard. Clinicians need to ensure they have sufficient training and follow current national foot health guidance to provide optimal foot health care and outcomes for their RA patients.